Document Detail


Immunomodulatory effect of the treatment of Graves' disease on antigen-specific monocyte procoagulant activity production.
MedLine Citation:
PMID:  2448069     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The monocyte procoagulant activity (PCA) production assay has been shown to be a good parameter of cell-mediated immunity. We have studied antigen-specific PCA production in peripheral blood mononuclear cells from patients with Graves' disease to determine the effect of the treatment on the cell-mediated immune response. Peripheral blood mononuclear cells from patients with untreated or relapsed Graves' disease produced significantly greater PCA with thyroid antigen stimulation than those from normal subjects. Patients both on antithyroid drugs in the hyperthyroid state and within 3 months post-131I therapy also produced significantly larger amount of PCA than normal subjects. However, there was no significant difference in PCA production with thyroid antigen stimulation between normal subjects and patients on anti-thyroid drugs in the euthyroid state, or patients over 3 months post-131I therapy. The ratio of positive to negative PCA production in patients on anti-thyroid drugs in the euthyroid state or over 3 months post-131I therapy was significantly lower than in untreated or relapsed Graves' disease patients. Mononuclear cells from patients on propylthiouracil responded to propylthiouracil in vitro by production of PCA. Cells from normal subjects, untreated Graves' disease patients, or patients with Hashimoto's thyroiditis did not produce PCA with propylthiouracil stimulation. Mononuclear cells from patients who were on propylthiouracil for more than 3 months produced greater PCA than those on the drug for less than 3 months, suggesting sensitization of lymphocytes to propylthiouracil during the course of treatment. However, after 131I therapy, they gradually became unresponsive to propylthiouracil. This study has shown that the activity of the antigen-specific response assessed by PCA production in mononuclear cells from Graves' disease patients declined after treatment, suggesting that the treatment exerted immunomodulatory effects.
Authors:
M Iitaka; Y Iwatani; H C Gerstein; V V Row; R Volpé
Related Documents :
16533439 - Euthyroid sick syndrome in trauma patients with severe inflammatory response syndrome.
12161479 - Arterial embolization: a novel approach to thyroid ablative therapy for graves' disease.
1516339 - The sonographic appearances in postpartum thyroiditis.
9215269 - Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, ...
15653659 - Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid c...
12407349 - The results of ultrasound-guided fine-needle aspiration biopsy for evaluation of nodula...
2048539 - Radiocontrast-associated renal dysfunction: incidence and risk factors.
4035839 - Urolithiasis in acromegaly.
8942739 - Shwachman syndrome: exocrine pancreatic dysfunction and variable phenotypic expression.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  27     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  1987 Sep 
Date Detail:
Created Date:  1988-03-18     Completed Date:  1988-03-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  321-30     Citation Subset:  IM    
Affiliation:
Endocrinology Research Laboratory, Wellesley Hospital, University of Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Blood Coagulation Factors / analysis,  immunology*
Epitopes
Female
Graves Disease / blood,  immunology*,  therapy
Humans
Immunity, Cellular
Iodine Radioisotopes / therapeutic use
Male
Middle Aged
Propylthiouracil / therapeutic use
Chemical
Reg. No./Substance:
0/Blood Coagulation Factors; 0/Epitopes; 0/Iodine Radioisotopes; 0/leukocyte procoagulant activity; 51-52-5/Propylthiouracil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Monitoring hepatocellular carcinoma by using a monoclonal immunoenzymometric assay for alpha-fetopro...
Next Document:  The effect of oral glucose on the leucocyte sodium pump in normal and obese subjects.